Publications — Semenov Lab | Harvard Dermatology AI Research

Br J Dermatol 2026

Impact of clinicopathological features on prognosis of thin melanomas: a retrospective cohort analysis

Beagles et al., Semenov YR

View Article

JAAD Int 2026

Quantifying the risk of drug-associated skin hyperpigmentation relative to the general population: A national cohort study using TriNetX

Cheng et al., Semenov YR

View Article

JAMA Dermatol 2026

Identification of Risk Factors for Acral Melanoma in US Veterans

Hwang et al., Semenov YR

View Article

JAAD Int 2026

Development and validation of the Oxford Attitudes to Artificial Intelligence in Medicine Scale

Kantor et al., Semenov YR

View Article

J Am Acad Dermatol 2026

Thromboembolic risk in dermatomyositis patients treated with intravenous immunoglobulin: A retrospective cohort study using the TriNetX database

Khattab et al., Semenov YR

View Article

J Am Acad Dermatol 2026

Risk and protective factors for uveal melanoma: Evidence for a protective role of autoimmune and immune-mediated conditions

Lu et al., Semenov YR

View Article

JCI Insight 2026

Somatic mutations reveal hyperactive Notch signaling in prurigo nodularis

Rajeh et al., Semenov YR

View Article

JAMA Dermatol 2026

Cutaneous Eruptions and Lifileucel/Interleukin 2 in Individuals With Metastatic Melanoma

Said et al., Semenov YR

View Article

JAMA Netw Open 2026 New

Systemic Glucocorticoid Immunosuppression and Survival Among Immune Checkpoint Inhibitor Recipients

Wan et al., Semenov YR

PDF

J Invest Dermatol 2026

Incubating artificial intelligence initiatives and careers in dermatology

Wongvibulsin et al., Semenov YR

View Article

Machine Learning Research 2025

Multi-modal foundation models for computational pathology: a survey

Li D, Wan G et al., Semenov YR

Med 2025

Precision phenotyping for curating research cohorts of patients with unexplained post-acute sequelae of COVID-19

Azhir et al., Semenov YR

View Article

J Am Acad Dermatol 2025

Type 2 immunity links eczematous and lichenoid eruptions caused by immune checkpoint inhibitors

Azin et al., Semenov YR

PDF

JAAD Int 2025

Exposure to intravenous immunoglobulin is associated with increased mortality in patients on immune checkpoint inhibitors: A population-based cohort study

Cheng et al., Semenov YR

View Article

JAMA Dermatol 2025

Validating the Use of ICD-10 Codes for Identifying Vitiligo

Cheng et al., Semenov YR

View Article

Int J Dermatol 2025

Double Trouble: A Case Series on Dual Morphology Cutaneous Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors

Ebriani et al., Semenov YR

View Article

NPJ Digit Med 2025

Academia loses its grip on digital health solutions as innovation in artificial intelligence shifts towards industry

Hijaz et al., Semenov YR

View Article

J Am Acad Dermatol 2025

Nivolumab/relatlimab-associated cutaneous immune-related adverse events in patients treated for advanced melanoma: A multicenter retrospective cohort study

Hijaz et al., Semenov YR

View Article

J Am Acad Dermatol 2025

A retrospective cohort study of the time between prior antibiotics and checkpoint inhibitors and association with survival in melanoma patients

Hirner et al., Semenov YR

View Article

Nat Commun 2025

Hepatitis B virus promotes liver cancer by modulating the immune response to environmental carcinogens

Huang et al., Semenov YR

View Article

J Immunother Cancer 2025

Long-term mortality outcomes among immunotherapy recipients treated with dupilumab for the management of cutaneous immune-related adverse events

Khattab et al., Semenov YR

PDF

J Am Acad Dermatol 2025

Clinicopathologic attributes and downstream outcomes of mucosal melanomas: A multihospital cohort study

Khattab et al., Semenov YR

View Article

J Invest Dermatol 2025

Geotemporal Analysis of Melanoma Incidence and Mortality Identifies Distinct Clusters of Trends within the United States Between 2001 and 2019

Latoni et al., Semenov YR

View Article

JID Innov 2025

Langerhans Cells Directly Interact with Resident T Cells in the Human Epidermis

Oka et al., Semenov YR

View Article

J Proteomics 2025

Comprehensive biobanking strategy with clinical impact at the European Cancer Moonshot Lund Center

Oskolas et al., Semenov YR

View Article

J Eur Acad Dermatol Venereol 2025

Seasonal and geographic variation in cutaneous immune-related adverse events after treatment with immune checkpoint inhibitors

Rajeh et al., Semenov YR

View Article

J Eur Acad Dermatol Venereol 2025

Surgical margin reduction in excision of cutaneous melanoma: A retrospective analysis

Rajeh et al., Semenov YR

View Article

Dermatol Clin 2025

The Current State and Future Prospects for Artificial Intelligence in Dermatology

Thang et al., Semenov YR

PDF

J Immunother Cancer 2024

Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy

Chen et al., Semenov YR

PDF

Hematol Oncol Clin North Am 2024

Cutaneous Imaging Techniques

Khattab et al., Semenov YR

View Article

J Am Acad Dermatol 2024

Differential time series analysis shows deceleration in melanoma mortality prior to the widespread use of highly effective therapies

Latoni et al., Semenov YR

View Article

J Am Acad Dermatol 2024

Cutaneous immune-related adverse event burden and effect on immunotherapy: A retrospective review

Le et al., Semenov YR

PDF

Nat Commun 2024

Statin prevents cancer development in chronic inflammation by blocking interleukin 33 expression

Park et al., Semenov YR

View Article

Clin Transl Med 2024

Mitochondrial dysfunction and immune suppression in BRAF V600E-mutated metastatic melanoma

Pinto de Almeida et al., Semenov YR

View Article

JAMA Dermatol 2024 Viewpoint

Adjuvant Immunotherapy in Stage II Melanoma-Further Risk Stratification is Needed

Rashdan et al., Semenov YR

PDF

J Am Acad Dermatol 2024

Timing of cutaneous immune-related adverse events impacts survival in patients with cancer treated with immune-checkpoint inhibitors

Rashdan et al., Semenov YR

View Article

J Am Acad Dermatol 2024

Associations between dermatologic immune-related adverse event morphologies and systemic immunomodulatory/immunosuppressive treatment

Reardon et al., Semenov YR

View Article

J Am Acad Dermatol 2024

Checkpoint inhibitor antibody type influences the development of cutaneous immune-related adverse events: A multi-institutional study

Roster et al., Semenov YR

View Article

Br J Dermatol 2024

De novo autoimmune connective tissue disease and mortality in patients treated with anti-programmed death receptor-1 and anti-programmed death-ligand 1 therapy

Tang et al., Semenov YR

View Article

Lancet Oncol 2024

Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study

Wan et al., Semenov YR

PDF

Brief Bioinform 2024

SpatialCells: automated profiling of tumor microenvironments with spatially resolved multiplexed single-cell data

Wan et al., Semenov YR

PDF

Br J Dermatol 2024

Cancer type and histology influence cutaneous immunotherapy toxicities: a multi-institutional cohort study

Wan et al., Semenov YR

PDF

J Am Acad Dermatol 2024

Pre-existing inflammatory disease predicts cutaneous immunotherapy toxicity development: A multi-institutional cohort study

Wan et al., Semenov YR

PDF

J Am Acad Dermatol 2024

Development and validation of time-to-event models to predict metastatic recurrence of localized cutaneous melanoma

Wan et al., Semenov YR

PDF

Immunol Rev 2023

Cutaneous immune-related adverse events from immune checkpoint inhibitor therapy: Moving beyond 'maculopapular rash'

Allais et al., Semenov YR

View Article

J Am Acad Dermatol 2023

Noncutaneous immune-related adverse events predict overall and progression-free survival in patients with cutaneous toxicities after immune checkpoint inhibitor therapy

Asdourian et al., Semenov YR

View Article

J Am Acad Dermatol 2023

Development of multiple cutaneous immune-related adverse events among cancer patients after immune checkpoint blockade

Asdourian et al., Semenov YR

View Article

J Am Acad Dermatol 2023

Morphologic characteristics of cutaneous immune-related adverse events in patients receiving immune checkpoint inhibitors combined with other anticancer therapies

Asdourian et al., Semenov YR

View Article

J Am Acad Dermatol 2023

Evaluating patterns of co-occurrence between cutaneous and noncutaneous immune-related adverse events after immune checkpoint inhibitor therapy

Asdourian et al., Semenov YR

View Article

Arch Dermatol Res 2023

Reduced serum pyridoxine and 25-hydroxyvitamin D levels in adults with chronic pruritic dermatoses

Gopinath et al., Semenov YR

View Article

J Drugs Dermatol 2023

Antimalarials are not Effective as Pre-Exposure Prophylaxis for COVID-19: A Retrospective Matched Control Study

Klebanov et al., Semenov YR

View Article

J Am Acad Dermatol 2023

Increased risk of cutaneous immune-related adverse events in patients treated with talimogene laherparepvec and immune checkpoint inhibitors

Leung et al., Semenov YR

PDF

J Am Acad Dermatol 2023

Patterns in utilization of health care services and medications among patients with cutaneous immune-related adverse events

Leung et al., Semenov YR

View Article

J Am Acad Dermatol 2023

Influence of melanoma type on incidence and downstream implications of cutaneous immune-related adverse events

Nguyen et al., Semenov YR

PDF

Arch Dermatol Res 2023

A cross-sectional analysis of trends in dermatology practice size in the United States from 2012 to 2020

Parthasarathy et al., Semenov YR

View Article

J Am Acad Dermatol 2023

Underuse of sentinel lymph node biopsy for early-stage melanoma

Rajeh et al., Semenov YR

PDF

J Am Acad Dermatol 2023

Recurrence and survival in early-stage acral lentiginous melanoma: A retrospective analysis

Roster et al., Semenov YR

PDF

JAMA Dermatol 2023

Use of 3-Dimensional Stereophotogrammetry to Detect Disease Progression in Craniofacial Morphea

Shaw et al., Semenov YR

View Article

J Am Acad Dermatol 2023

Tumor-infiltrating lymphocytes as a predictive biomarker of cutaneous immune-related adverse events

Stephens et al., Semenov YR

PDF

J Invest Dermatol 2023

A Polygenic Risk Score for Predicting Racial and Genetic Susceptibility to Prurigo Nodularis

Vasavda et al., Semenov YR

View Article

JAAD Int 2023

The impact of stage-related features in melanoma recurrence prediction: A machine learning approach

Wan et al., Semenov YR

PDF

J Drugs Dermatol 2023

Seasonal Patterns in Tetracycline-Associated Hyperpigmentation Among Patients With Acne Vulgaris

Young et al., Semenov YR

View Article

J Am Acad Dermatol 2023

Differences in risk of tetracycline-associated hyperpigmentation between racial and ethnic groups

Young et al., Semenov YR

View Article

J Am Acad Dermatol 2023

Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients: A multi-institutional cohort study

Zhang et al., Semenov YR

PDF

J Am Acad Dermatol 2022

Association between serum lactate dehydrogenase and cutaneous immune-related adverse events among patients on immune checkpoint inhibitors for advanced melanoma

Asdourian et al., Semenov YR

View Article

JAAD Int 2022

Identification of cutaneous immune-related adverse events by ICD codes and medication administration

Chen et al., Semenov YR

PDF

J Am Acad Dermatol 2022

Racial and ethnic disparities in inpatient health care utilization for mycosis fungoides

Choi et al., Semenov YR

View Article

JAMA Dermatol 2022

Risk of Hematologic Cancer in Patients With Undifferentiated Pruritus

Deng et al., Semenov YR

View Article

Nat Med 2022

Germline variants associated with toxicity to immune checkpoint blockade

Groha et al., Semenov YR

PDF

J Invest Dermatol 2022

Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study

Le et al., Semenov YR

PDF

J Dermatolog Treat 2022

Cutaneous adverse events of immune checkpoint inhibitor therapy: incidence and types of reactive dermatoses

Le et al., Semenov YR

PDF

J Am Acad Dermatol 2022

Reply to COVID-19 vaccination in IMID patients receiving rituximab

Pahalyants et al., Semenov YR

View Article

J Am Acad Dermatol 2022

Immunosuppressive biologics did not increase the risk of COVID-19 or subsequent mortality: A retrospective matched cohort study

Pahalyants et al., Semenov YR

View Article

J Am Acad Dermatol 2022

Racial and socioeconomic differences in acral lentiginous melanoma outcomes

Raval et al., Semenov YR

View Article

J Am Acad Dermatol 2022

Validation of International Classification of Diseases Tenth Revision code for prurigo nodularis

Roh et al., Semenov YR

View Article

JAMA Dermatol 2022

Risk Factors for the Development of Bullous Pemphigoid in US Patients Receiving Immune Checkpoint Inhibitors

Said et al., Semenov YR

PDF

J Am Acad Dermatol 2022

Understanding racial disparities in prurigo nodularis

Sutaria et al., Semenov YR

PDF

J Invest Dermatol 2022

Cutaneous Transcriptomics Identifies Fibroproliferative and Neurovascular Gene Dysregulation in Prurigo Nodularis

Sutaria et al., Semenov YR

View Article

J Dermatol Sci 2022

Racial differences in dysregulation of the renin-angiotensin-aldosterone system in patients with prurigo nodularis

Sutaria et al., Semenov YR

View Article

J Invest Dermatol 2022

Cluster Analysis of Circulating Plasma Biomarkers in Prurigo Nodularis Reveals a Distinct Systemic Inflammatory Signature in African Americans

Sutaria et al., Semenov YR

View Article

J Am Acad Dermatol 2022

Racial disparities in mortality among patients with prurigo nodularis: A multi-center cohort study

Sutaria et al., Semenov YR

PDF

J Natl Cancer Inst 2022

Pre-Existing Autoimmune Disease and Mortality in Patients Treated with Anti-PD-1 and Anti-PD-L1 Therapy

Tang et al., Semenov YR

PDF

JAMA Dermatol 2022

Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-PD-1 and Anti-PD-L1 Therapy

Tang et al., Semenov YR

PDF

JAMA Dermatol 2022

Validation of Case Identification for Melasma Using ICD-10 Codes

Theodosakis et al., Semenov YR

View Article

J Immunother Cancer 2022

Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors

Tiu et al., Semenov YR

PDF

NPJ Precis Oncol 2022

Prediction of early-stage melanoma recurrence using clinical and histopathologic features

Wan et al., Semenov YR

PDF

Br J Dermatol 2022

Latent class analysis identification of prurigo nodularis comorbidity phenotypes

Wongvibulsin et al., Semenov YR

View Article

J Am Acad Dermatol 2022

Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis

Wongvibulsin et al., Semenov YR

PDF

Br J Dermatol 2021

Current measures are not sufficient: an interview-based qualitative assessment of quality of life in cutaneous T-cell lymphoma

Bhat et al., Semenov YR

View Article

BMC Med 2021

Evolving phenotypes of non-hospitalized patients that indicate long COVID

Estiri et al., Semenov YR

View Article

Br J Dermatol 2021

Biologics utilization for psoriasis is lower in black compared with white patients

Hodges et al., Semenov YR

View Article

J Immunother Cancer 2021

Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors

Kalinich et al., Semenov YR

PDF

Oncologist 2021

Risk of COVID-19 in Patients with Cancer Receiving Immune Checkpoint Inhibitors

Klebanov et al., Semenov YR

View Article

Oncologist 2021

Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events

Molina et al., Semenov YR

View Article

J Am Acad Dermatol 2021

Ethnic variations in scalp pruritus and hair loss

Osemwota et al., Semenov YR

View Article

J Am Acad Dermatol 2021

Worldwide seasonal variation in search volume for cutaneous warts from 2004 to 2019

Phelan et al., Semenov YR

View Article

J Am Acad Dermatol 2021

Health-related quality of life in patients with malignant melanoma by stage and treatment status

Rosenberg et al., Semenov YR

View Article

J Am Acad Dermatol 2021

Psoriasis and mortality in the United States: Data from the National Health and Nutrition Examination Survey

Semenov YR et al.

PDF

Br J Dermatol 2021

Itch in skin of colour: a multicentre cross-sectional study

Sutaria et al., Semenov YR

View Article

J Invest Dermatol 2021

A Nationwide Study of Prurigo Nodularis: Disease Burden and Healthcare Utilization in the United States

Wongvibulsin et al., Semenov YR

View Article

Dermatol Surg 2021

Surgical Outcomes and Risk Factors for Apical Triangle Basal Cell Carcinomas: A Single Institution Analysis

Zhang et al., Semenov YR

View Article

J Immunother Cancer 2021

Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer

Zubiri et al., Semenov YR

View Article

Medicines (Basel) 2020

Comorbidities Associated with Granuloma Annulare: A Cross-Sectional, Case-Control Study

Almazan et al., Semenov YR

View Article

Int J Pediatr Otorhinolaryngol 2020

Association between vertigo, cognitive and psychiatric conditions in US children

Bigelow et al., Semenov YR

PDF

Int J Womens Dermatol 2020

Diagnostic concordance of clinical diagnosis, tissue culture, and histopathology testing for skin and soft tissue infections

Herbosa et al., Semenov YR

View Article

J Eur Acad Dermatol Venereol 2020

Risk of cancer in psoriasis: study of a nationally representative sample of the US population

Herbosa et al., Semenov YR

PDF

J Eur Acad Dermatol Venereol 2020

Clinical severity measures and quality-of-life burden in patients with mycosis fungoides and Sézary syndrome

Herbosa et al., Semenov YR

View Article

J Clin Aesthet Dermatol 2020

A Dermatologist's Guide to Implementation of Gene Expression Profiling in the Management of Melanoma

Kwatra et al., Semenov YR

View Article

Br J Dermatol 2020

Health-related quality of life and economic implications of cutaneous T-cell lymphoma

Semenov YR et al.

PDF

J Natl Med Assoc 2019

Racial Disparities in the Clinical Presentation and Prognosis of Patients with Mycosis Fungoides

Huang et al., Semenov YR

View Article

Medicines (Basel) 2019

Proteomic and Phosphoproteomic Analysis Reveals that Neurokinin-1 Receptor (NK1R) Blockade with Aprepitant in Human Keratinocytes Activates a Distinct Subdomain of EGFR Signaling

Kwatra et al., Semenov YR

PDF

J Rheumatol 2019

Association Between Psoriasis with Arthritis and Hearing Impairment in US Adults

Semenov YR et al.

View Article

Laryngoscope Investig Otolaryngol 2018

Health-related quality of life and economic burden of vestibular loss in older adults

Agrawal et al., Semenov YR

View Article

J Am Acad Dermatol 2018

Ethnic differences and comorbidities of 909 prurigo nodularis patients

Boozalis et al., Semenov YR

View Article

J Dermatolog Treat 2018

Food and drug administration approval process for dermatology drugs in the United States

Boozalis et al., Semenov YR

View Article

Br J Dermatol 2018

Seasonality of hair loss: a time series analysis of Google Trends data 2004-2016

Hsiang et al., Semenov YR

View Article

J Dermatolog Treat 2018

Racial disparities in the management of acne: evidence from the National Ambulatory Medical Care Survey

Rogers et al., Semenov YR

View Article

Audiol Neurootol 2017

Quality of Life and Cost-Effectiveness of Cochlear Implants: A Narrative Review

Crowson et al., Semenov YR

PDF

J Am Acad Dermatol 2017

Seasonal variation of itch: A study using real-time data from 2004 to 2016

Grandhi et al., Semenov YR

PDF

J Assoc Res Otolaryngol 2016

Impaired Vestibular Function and Low Bone Mineral Density: Data from the Baltimore Longitudinal Study of Aging

Bigelow et al., Semenov YR

PDF

J Neurol Neurosurg Psychiatry 2016

Vestibular vertigo and comorbid cognitive and psychiatric impairment

Bigelow et al., Semenov YR

PDF

J Gerontol A Biol Sci Med Sci 2016

Association Between Vestibular and Cognitive Function in U.S. Adults

Semenov YR et al.

PDF

J Am Geriatr Soc 2015

Association Between Visuospatial Ability and Vestibular Function in the Baltimore Longitudinal Study of Aging

Bigelow et al., Semenov YR

PDF

Gerontol Geriatr Med 2015

Vestibular Function and Activities of Daily Living: Analysis of the 1999 to 2004 National Health and Nutrition Examination Surveys

Harun et al., Semenov YR

PDF

Otol Neurotol 2015

The Role of Obliteration in the Achievement of a Dry Mastoid Bowl

Harun et al., Semenov YR

View Article

JAMA Otolaryngol Head Neck Surg 2014

Bilateral Vestibular Deficiency: Quality of Life and Economic Implications

Sun et al., Semenov YR

View Article

Otolaryngol Head Neck Surg 2013

Postoperative urinary tract infection and short-term outcomes and costs in head and neck cancer surgery

Chan et al., Semenov YR

PDF

Ear Hear 2013

Age-dependent cost-utility of pediatric cochlear implantation

Semenov YR et al.

PDF

Laryngoscope 2012

The effect of deep venous thrombosis on short-term outcomes and cost of care after head and neck cancer surgery

Hennessey et al., Semenov YR

PDF

Otolaryngol Clin North Am 2012

Cochlear implants: clinical and societal outcomes

Semenov YR et al.

PDF

Laryngoscope 2012

The effect of pneumonia on short-term outcomes and cost of care after head and neck cancer surgery

Semenov YR et al.

PDF